EGFR and neoplasm: In HA-rich RKO tumors, intravenous administration of EGFR × HYAL effectively inhibited tumor growth, achieving a tumor growth inhibition (TGI) of 58% compared to 37% for EGFR × Null (Figure 2C), without affecting the mice’s body weight (Supplementary Figure S4).